Clinical trial for the washed microbiota transplantation in the treatment of novel coronavirus pneumonia (COVID-19) patients suspected with gut microbiota dysbiosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032737

Enrollment

Unknown

Registered

2020-05-08

Start date

2020-05-08

Completion date

Unknown

Last updated

2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Routine treatment group:Routine treatment

WMT group:Washed microbiota transplantation

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. COVID-19 patients accompanied with gastrointestinal symptoms; 2. COVID-19 patients accompanied with antibiotic-associated diarrhea

Exclusion criteria

Exclusion criteria: (1) Critical type of COVID-19 according to COVID-19 diagnosis and treatment guidelines in China (7th edition); (2) Gastrointestinal perforation; (3) Gastrointestinal obstruction; (4) Recent history of intestinal fistula; (5) Disturbance of consciousness; (6) Gastrointestinal hemorrhage; (7) Malignant tumors; (8) Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
SARS-Cov-2 nucleic acid test;	—

Secondary

Measure	Time frame
Fasting blood glucose;Liver function;Renal function;Electrolyte;Muscle enzyme;Myoglobin;D-dimer;Blood routine test;C-reactive protein;Erythrocyte sedimentation rate;Procalcitonin;Interleukin-2;Interleukin-6;Tumor necrosis factor alpha;Interferon gama;Lymphocyte subsets of peripheral blood;Intestinal barrier function test;Oxygenation index;Blood gas analysis;Pneumonia severity index ;APACHE II score;	—

Measure

Time frame

Fasting blood glucose;Liver function;Renal function;Electrolyte;Muscle enzyme;Myoglobin;D-dimer;Blood routine test;C-reactive protein;Erythrocyte sedimentation rate;Procalcitonin;Interleukin-2;Interleukin-6;Tumor necrosis factor alpha;Interferon gama;Lymphocyte subsets of peripheral blood;Intestinal barrier function test;Oxygenation index;Blood gas analysis;Pneumonia severity index ;APACHE II score;

—

Countries

China

Contacts

Public ContactLi-Hao Wu

The First Affiliated Hospital of Guangdong Pharmaceutical University

wulihao888@126.com+86 13660635861

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026